Nalbuphine combined with midazolam for outpatient sedation. An assessment in fibreoptic bronchoscopy patients.
Forty patients who required day case fibreoptic bronchoscopy were sedated with either nalbuphine 0.2 mg/kg and midazolam 0.05 mg/kg (n = 20), or midazolam 0.05 mg/kg alone (n = 20). Extra midazolam was administered when required. The degree of respiratory depression measured by arterialised venous carbon dioxide levels was recorded together with heart rate, arterial blood pressure, respiratory rate and sedation score, before administration of the drugs and at regular intervals thereafter. Patients who received nalbuphine had slightly higher carbon dioxide levels but respiratory rate and cardiovascular changes were similar in both groups. The addition of nalbuphine to midazolam improves the quality of sedation but prolongs the recovery time and increases the incidence of side effects.
D000553:Ambulatory Care; D001999:Bronchoscopy; D002245:Carbon Dioxide / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D005336:Fiber Optic Technology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage*; D008297:Male; D008874:Midazolam / Q000008:administration & dosage* / Q000494:pharmacology; D008875:Middle Aged; D009019:Morphinans / Q000008:administration & dosage*; D009266:Nalbuphine / Q000008:administration & dosage* / Q000494:pharmacology; D012119:Respiration / Q000187:drug effects
D006993:Hypnotics and Sedatives; D009019:Morphinans; D002245:Carbon Dioxide; D009266:Nalbuphine; D008874:Midazolam